Cartesian Therapeutics (RNAC) Cash & Equivalents (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Cash & Equivalents data on file, last reported at $118.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $118.6 million, down 34.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.6 million (down 34.25% YoY), and the FY2025 annual result was $125.1 million, down 41.14% from the prior year.
• Cash & Equivalents slipped to $118.6 million in Q1 2026 per RNAC's latest filing, from $125.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $219.2 million in Q3 2024 and troughed at $76.9 million in Q4 2023.
• A 5-year average of $130.3 million and a median of $118.6 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 176.44% in 2024, then sank 41.14% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $106.4 million in 2022, then fell by 27.74% to $76.9 million in 2023, then surged by 176.44% to $212.6 million in 2024, then sank by 41.14% to $125.1 million in 2025, then decreased by 5.19% to $118.6 million in 2026.
• Business Quant data shows RNAC's Cash & Equivalents at $118.6 million in Q1 2026, $125.1 million in Q4 2025, and $143.4 million in Q3 2025.